Zydus Lifesciences to launch Phase 2 Parkinson’s disease trial of ZYIL1

Zydus Lifesciences Limited, a globally recognized pharmaceutical company, has recently obtained the USFDA's approval to commence Phase II clinical study of its NLRP3 inhibitor, ZYIL1, ... Read More